Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Brien, S. M.
Right arrow Articles by Faderl, S.
Right arrow Search for Related Content
PubMed
Right arrow Articles by O'Brien, S. M.
Right arrow Articles by Faderl, S.

A La Carte Therapy of Specific Acute Lymphocytic Leukemia Subsets

Susan M. O'Brien, MD, Deborah A. Thomas, MD, and Stefan Faderl, MD

From the Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Susan M. O'Brien, MD, Professor and Internist, Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030; e-mail: sobrien{at}mdanderson.org

Overview: Acute lymphocytic leukemia (ALL) is increasingly recognized as a highly heterogenous disease comprising many entities for which different treatment strategies may be applied.1,2 This review focuses on two specific subtypes of ALL, Philadelphia chromosome-positive (Ph+) disease and mature B-cell acute leukemia or Burkitt leukemia. Historically, these two subsets were among the worst prognostic subsets of ALL. Even if patients entered complete remission, relapses were frequent, and very few patients were cured. Recent advances in treatment for both of these subsets have dramatically changed the natural history of the disease and enabled a substantial fraction of patients to be cured.